Yahoo Web Search

Search results

  1. Nov 18, 2022 · Executive Summary. Based on our data team's research, Richard A. Gonzalez is the AbbVie's CEO. AbbVie has 47,000 employees, of which 47 are in a leadership position. Here are further demographic highlights of the leadership team: The AbbVie executive team is 38% femaleand 62% male. 64%of the management team is White.

  2. Feb 20, 2024 · AbbVie Inc.'s founding CEO Richard Gonzalez will step down July 1, the drugmaker said Tuesday, and will be replaced by the company's current president and chief operating officer, Robert Michael.

  3. Mar 11, 2024 · AbbVie CEO made $25.6 million in final full year as chief. In his last full year as AbbVie CEO, Richard Gonzalez saw his 2023 paycheck shrink slightly amid declining revenues as the pharmaceutical ...

  4. May 7, 2024 · Robert A. Michael. Chief Executive Officer. Rob Michael is the Chief Executive Officer of AbbVie, a global biopharmaceutical company that employs approximately 50,000 people worldwide and has provided innovative medicines and products to more than 60 million people in over 175 countries. Mr.

  5. Jan 10, 2023 · "This collaboration will give AbbVie access to Anima's leading technology platform and deep expertise in mRNA biology and will help further strengthen AbbVie's world class capabilities in discovering and developing drugs to make a difference in patient's lives," said Jonathon Sedgwick, Ph.D., vice president and global head of discovery research ...

  6. www.europeanpharmaceuticalreview.com › news › 214506AbbVie announces its new CEO

    Feb 23, 2024 · Robert Michael will become AbbVie’s new CEO on 1 July 2024. Richard Gonzalez will retire as the company’s CEO to become Executive Chairman, having served as the company’s CEO since its launch in 2013, AbbVie noted. AbbVie’s upcoming C-suite succession. Robert has had “a tremendous impact” on AbbVie, according to Richard Gonzalez.

  7. Leveraging technology to accelerate sciences. We do whatever it takes to help develop medicines and solutions, knowing time is of the essence. Our ever-expanding scientific capabilities help us get there first. In fact, 80% of the therapies in our pipeline are considered first-in-class. Our cutting-edge technologies are applied end-to-end ...

  1. People also search for